RLMD: Relmada Therapeutics, Inc. Stock

by  •  • Comments Off on RLMD: Relmada Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 111.34
Enterprise Value ($M) 107.25
Book Value ($M) 85.36
Book Value / Share 2.83
Price / Book 1.30
NCAV ($M) 85.31
NCAV / Share 2.83
Price / NCAV 1.31

Profitability (mra)
Return on Invested Capital (ROIC) -1.16
Return on Assets (ROA) -0.73
Return on Equity (ROE) -0.79

Liquidity (mrq)
Quick Ratio 8.00
Current Ratio 8.00

Balance Sheet (mrq) ($M)
Current Assets 97.51
Assets 97.55
Liabilities 12.19
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -103.70
Net Income -98.79
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -51.66
Cash from Investing 50.45
Cash from Financing -0.10

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-06 13G/A Perceptive Advisors Llc 0.00 -100.00
02-14 13G/A Rtw Investments, Lp 0.00 -100.00
02-14 13G/A Deep Track Capital, LP 6.79 -27.95
02-13 13G/A Vanguard Group Inc 4.35 -13.59
07-07 13G/A BlackRock Inc. 2.00 -67.51

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Fo
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 3,518 20,296 17.33
2024-05-01 5,025 61,273 8.20
2024-04-30 17,922 46,113 38.87
2024-04-29 29,701 70,612 42.06

(click for more detail)

Similar Companies
RGEN – Repligen Corporation RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc. RLYB – Rallybio Corporation
ROIV – Roivant Sciences Ltd.


Financial data and stock pages provided by
Fintel.io